There is new news on the fight against sexual dysfunction in women.  Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) has entered into global license and supply agreements with Procter & Gamble (NYSE: PG) under the consumer product giant’s Pharmaceuticals unit for the development and commercialization of prescription transdermal patches for the treatment of Hypoactive Sexual Desire Disorder [...]

There have always been some concerns about side-effects from drugs that treat erectile dysfunction or E.D.  Some are sudden blood pressure drops, hearing loss, and some are erections lasting four hours or more.  There are also other side-effects, but the newest may have a new twist: TEMPORARY AMNESIA!
A labeling approval change was approved this month [...]

Short sellers haven’t just eased up on betting against financial stocks.  If you look at the major biotech stocks not involved in mergers you will see an across the board drop in the short interest in major biotechs.  Below we have show the dates and the changes to represent each of the major names:

Amgen (AMGN) [...]

The Board of Directors of Genentech, Inc. (NYSE: DNA) had already appointed a special committee to review the .00 cash buyout for the rest of the company that Roche did not already own.  The committee responded today with a “NO, WE WANT MORE!” response to Roche.
In the press release, it announced that it has unanimously [...]

Cloning may invoke more controversy than any topic, short of a few that we won’t go into.  But there is a new pact out there regarding animal cloning that investors may be playing ahead.  Geron Corporation (NASDAQ: GERN) and Exeter Life Sciences, Inc. announced a merger of Start Licensing, Inc., a joint venture between Geron [...]

These are some of the analyst calls impacting biotech, medical, and healthcare stocks right at the open this Thursday morning:

Auxilium Pharmaceuticals (AUXL) Cut to Neutral from BUY at B of A.
Avalon Pharma (AVRX) Cut to Hold from Buy at Cantor Fitzgerald.
Cepheid (CPHD) Cut to Neutral from Buy at UBS.
Micrus Endovascular (MEND) Started as Hold at [...]

Billionaire activist investor Carl Icahn showed his biotech and medical holdings yesterday, with the ownership filing date as of June 30, 2008.  Here is a snapshot of his filed holdings:

Adventrx Pharmaceuticals Inc. (AMEX: ANX)3.459 million shares, small position for Icahn
Amicus Therapeutics, Inc. (NASDAQ: FOLD) 201,940 shares, small stake and small interest
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) [...]

In July 2008, Gen-Probe Inc. (NASDAQ: GPRO) was notified that certain blood screening assays manufactured by the company for Novartis’ (NYSE: NVS) Vaccines & Diagnostics unit and sold outside of the United States might have been improperly stored at a Novartis warehouse in Singapore.
The company investigated the product performance and on August 12, 2008 Gen-Probe [...]

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) is about to see its first corporate and investor event tomorrow of this kind.  August 13 will be the EX-DATE for its 2-for-1 stock split which was announced back on July 29.
What is sort of odd is that this stock reached 0 briefly during the summer months way back in [...]

Altus Pharmaceuticals Inc. (ALTU) is trading lower after mixed results in a cystic fibrosis Phase III trial.  Unfortunately, the results weren’t quite what the investment community was hoping for.
The study met some of the endpoints, but there were hopes for better results that had been indicated and some results varied geographically between those in the [...]